Non-Hodgkin's Lymphoma Update:

You are here: Home: NHLU 4 2005 : Editor's Office

EDITOR
Neil Love, MD

ASSOCIATE EDITORS
Michelle Paley, MD
Richard Kaderman, PhD

WRITERS
Lilliam Sklaver Poltorack,
PharmD
Sally Bogert, RNC, WHCNP
Douglas Paley
Kathryn Ault Ziel, PhD

CME DIRECTOR
Michelle Paley, MD

CONTENT VALIDATION
Margaret Peng

DIRECTOR, CREATIVE
AND COPY EDITING
Aura Herrmann

ART DIRECTOR
Tamara Dabney

SENIOR DESIGNER
Christina Brigham

DESIGN QUALITY
CONTROL DIRECTOR
Ben Belin

GRAPHIC DESIGNERS
Jason Cunnius
Fernando Rendina
Maria Schaefer

PRODUCTION EDITOR
Alexis Oneca

COPY EDITORS
Joy Davis
Pat Morrissey/Havlin
Cirri Nottage
Susan Petrone

PRODUCTION MANAGER
Patricia Kappes

AUDIO PRODUCTION
Frank Cesarano

TECHNICAL SERVICES
Arly Ledezma

WEB DESIGN
John Ribeiro

EDITORIAL ASSISTANTS
Catherine Marshall
Patricia McWhorter
Tere Sosa
Ginelle Suarez
Arlene Thorstensen

CONTACT INFORMATION:
Neil Love, MD
Director, Physician and Community Education

RESEARCH TO PRACTICE
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131
Fax: (305) 377-9998
Email: NLove@ResearchToPractice.net

FOR CME INFORMATION
Melissa Vives
Associate CME Administrator
Email: MVives@ResearchToPractice.net

This program is supported by education grants from Biogen Idec and Genentech BioOncology.

The audio tapes, compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.

Table of Contents

Top of Page

Table of Contents

Editor’s Note:
Is overall survival the only important endpoint in Phase III randomized clinical trials?

Bruce D Cheson, MD

- Select publications

Myron S Czuczman, MD

- Select publications

James O Armitage, MD

- Select publications

Faculty Disclosures

A CME Audio Series
and Activity

Editor's office